![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Torrent Pharma Broadens Losartan Potassium Recall
Torrent Pharma Broadens Losartan Potassium Recall
October 3, 2019
Torrent Pharmaceuticals expanded its recall of losartan potassium tablets to the consumer level due to the detection of trace amounts of N-Methylnitrosobutyric acid (NMBA), a probable carcinogen.
The company is only recalling certain lots of losartan-containing products that contained more than the acceptable daily intake levels of NMBA.
The expanded recall included an additional three lots of losartan potassium tablets and two lots of losartan potassium/hydrocholorothiazide tablets.
Upcoming Events
-
21Oct